4.5 Interaction with other medicinal products and other forms of interaction   
 No interaction studies evaluating use  of caplacizumab  with oral anticoagulants (e.g. vitamin K antagonists,  direct oral anticoagulants [DOAC] such as thrombin inhibitors  or factor Xa inhibitors) , antiplatelet agents, thrombolytic agents  such as urokinase, t 
 PA (e.g. alteplase) or heparin  have been performed ( see section 4.4 In the setting of concomitant use of oral anticoagulants, anti- platelet agents, thrombolytic agents or heparin).  
 5 